Astera Labs · one lens
Benjamin Graham on Astera Labs
Astera’s growth validates the business, but missing cash-flow and valuation inputs leave no measurable margin of safety after the stock fell from $319.74 to $303.62.
Astera Labs’ fiscal Q1 2026 earnings release, dated May 5, 2026, supplies the latest operating baseline for the July 17, 2026 market event: Mr. Market cut Astera 5.04%, to $303.62 from $319.74, a $16.12 decline. The release reported Q1 revenue of $308.4 million, up 93%, from about $159.8 million in Q1 2025. Astera’s 2025 filing reported revenue of $852.5 million, up 115.1%, or $456.2 million, from $396.3 million in 2024. The filing also reported 2025 net income of $219.1 million, compared with the $26.3 million net loss disclosed for 2023 in TEXXR’s IPO-filing coverage.
The supplied record cannot complete Graham’s intrinsic-value calculation from assets, earnings, dividends, and definite prospects. The supplied materials report no capex, depreciation, or free-cash-flow figure for Q1 2026 or 2025, and they report no period-over-period change for any of the three. The record also omits the current assets, liabilities, trailing earnings per share, seven-year average earnings, and dividend history needed for Graham’s defensive tests. The record therefore cannot verify conservative financing, continuous dividends, or Graham’s ceilings of 20 times trailing earnings and 25 times average earnings over the preceding seven years.
Astera’s customer mix makes its definite prospects less certain. The 2025 10-K, as summarized in the dossier, disclosed one customer above 70%—more than $596.75 million of $852.5 million in revenue—and the top three at roughly 86%, or about $733.15 million of $852.5 million. The February 2026 Amazon warrant filing ties up to 3.26 million shares to as much as $6.5 billion of future purchases, but those contractual ceilings are not current earnings. The dossier’s cited AMD roadmap record also says the Helios rack due in the second half of 2026 will use Broadcom switches rather than Astera switches.
The TEXXR coverage record contains exactly six articles from the September 2021 Series C record through the March 2024 trading-debut record. The corpus logged four articles in 2024 Q1, compared with an eight-quarter average of one, and then logged none after March 21, 2024. TEXXR’s graph carries nine Astera hyperedges—eight financial and one product—against zero partnership edges.
The record therefore supports business progress but cannot qualify the current operation as investment under Graham’s investment-versus-speculation test. The record leaves no defensible intrinsic-value range and thus no measured margin of safety. Graham’s framework treats that missing arithmetic, rather than the latest quote, as the controlling fact.
An editorial application of Benjamin Graham's published framework — not their actual view, affiliation, or advice.
Where this lens comes from
Benjamin Graham's framework is set out at the lens page, drawn from The Intelligent Investor, Security Analysis. This page applies it to Astera Labs and nothing else — the company's full record is in the dossier.